HIPEC improves survival in stage III epithelial ovarian cancer

0
0 / 5 (0 votos)

The Lancet Oncology

Fecha de publicación: 25 January 2018

DOI: https://doi.org/10.1016/S1470-2045(18)30065-2

Autores: Robert Stirrups

Background: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves outcomes in patients receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer, according to a recent study.

SEGUIR LEYENDO